Dr. Damir Janigro, PhD is the founder and CSO of Flocel Inc. and CEO of FloStroke, a Professor at CWRU, a member of the World Neurobiology Commission of ILAE, and Associate editor for Epilepsia, PLOS among other journals. He has over 30 years of experience and has received continuous support from the NIH since 1996. He is the inventor of the dynamic in vitro model of the BBB that constituted one of the founding blocks of 3D modeling of the cerebrovasculature. He invented S100B as a marker of BBB function and has for many years collaborated with top notch hospitals in the US and Europe to broaden the scope and use of this technology. He recently patented the use of S100B as marker of hemorrhagic transformation in stroke victims undergoing intra-arterial therapies as well as a POC device to aid in the diagnostic space. He has served on several NIH panels, has been part of three FDA application processes, served as Chairman for study sections for the American Heart Association and the Department of Defense. As a PI with a multimillion funding history, Dr. Janigro has been associated with neurosurgeons and neurointensivists since his post-doctoral years at the University of Washington (1994-1999) and as the Director of Cerebrovascular Research at the Cleveland Clinic (1999-2015). He has published extensively in the field of biomarkers and epilepsy.